1,028
Participants
Start Date
February 2, 2023
Primary Completion Date
September 29, 2025
Study Completion Date
September 29, 2026
Plasma biomarker levels
"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
RECRUITING
Glasgow Royal Infirmary, Glasgow
RECRUITING
New Victoria Hospital, Glasgow
RECRUITING
Queen Elizabeth University Hospital, Glasgow
University of Glasgow
OTHER
Roche Diagnostics GmbH
INDUSTRY
NHS Greater Glasgow and Clyde
OTHER